ArticleClinical kidney journal2026
Vaccine efficacy in CKD patients not on dialysis: a systematic review and meta-analysis.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with chronic kidney disease (CKD) have increased infection risk, contributing to higher rates of hospitalization and mortality. While vaccines can prevent or reduce the severity, data primarily focus on dialysis-dependent patients. This meta-analysis aimed to evaluate vaccine efficacy in non-dialysis CKD patients (CKD-ND). Methods: We systematically searched the MEDLINE, Embase, Scopus and OVID databases through April 2025 for randomized controlled and observational studies reporting the vaccine efficacy in stage 1-5 CKD-ND patients. Efficacy was assessed using laboratory markers (seroconversion, antibody titres) and clinical outcomes. The quality of the studies was assessed by ROBINS-I V2 and RoB2. A random effects model was used to estimate pooled effect size with 95% confidence interval. Results: Twenty-eight studies involving >500 000 participants were included covering hepatitis B virus (HBV), COVID-19, influenza, herpes zoster, pneumococcus and human papillomavirus (HPV) vaccines. Most studies were graded fair quality. Ten studies on HBV vaccination revealed a pooled seroconversion rate of 80% that decreased to 60% at 12 months post-vaccination. For COVID-19, the pooled anti-spike immunoglobulin G titre was 228.39 BAU/ml, with a reduced risk of COVID-19 infection following a boosting dose. Two doses of the influenza vaccine yielded higher seroconversion rates than a single dose, but the antibody levels declined over time, indicating waning immunity. The zoster vaccine showed a pooled adjusted hazard ratio of 0.74 for herpes zoster incidence compared with those who were unvaccinated. Pneumococcal vaccine elicited a modest transient response and was associated with reduced Conclusion: Vaccination in CKD-ND patients is associated with a high rate of seroconversion and seroprotection across multiple vaccines. However, these surrogate markers may not fully reflect clinical effectiveness. Further studies are needed to evaluate the impact of vaccination on demonstrated clinical outcomes, particularly infection-related morbidities and mortalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.